Advanced non-small-cell lung cancer: how to manage EGFR & HER2 exon 20 insertion mutation-positive disease Giulio Metro Andrea De Giglio, MD PhD @BiagioMd marco siringo Daniele Marinelli Luca Cantini Giuseppe Lamberti Giannis Mountzios et al #drugsincontext #nsclc #oncology drugsincontext.com/advanced-non-s…

New in @DrugsinContext Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease Daniele Marinelli marco siringo Giulio Metro @BiagioMd Gelibter #drugsincontext #nsclc #oncology #lungcancer #treatment drugsincontext.com/non-small-cell…

Adagrasib (Krazati) receives FDA accelerated approval for previously treated #KRAS G12C NSCLC joining sotorasib as a targeted therapy option for this relatively common genomic subset of lung cancer. #LCSM reuters.com/world/us/us-fd…

Great to see you all at the 'ESMO - The Christie NHS Preceptorship on #LungCancer 2023' in Manchester exploring multidisciplinary managemt, SoC & future perspectives. There are many #ESMOPreceptorship courses in 2023 covering a wide range of topics 👉 ow.ly/MblX50N7U3u #lcsm

😳😳😳 🇯🇵 ORR 90.9%, mPFS 31.0 months, and mOS not reached. Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR-Mutated Advanced Non-Squamous Non-Small Cell Lung Cancer: The OPAL Study. #LCSM sciencedirect.com/science/articl…

Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer mdpi.com/2569232 #mdpicancers via Cancers MDPI

Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment ⁦JCO Precision Oncology⁩ ⁦International Society of Liquid Biopsy⁩ ⁦Alessandro Russo⁩ ⁦Marzia Del Re, PharmD, PhD⁩ ⁦Geoff Oxnard MD⁩ ⁦The Tisch Cancer Institute⁩ ⁦ASCO⁩ ascopubs.org/doi/10.1200/PO…

Our RW study of first-line pembrolizumab plus platinum-pemetrexed in Italian patients with advanced non-squamous lung cancer is out on Eur J Cancer! ➡️ 1068 pts ➡️ mOS 16.1m, mPFS 9.9m, ORR 43.4% ➡️ Favourable outcomes in PD-L1 < 1% 👉 ejcancer.com/article/S0959-… Great teamwork!

Proud to have contributed to this systematic review led by Gabriella Gentile and Matteo Lambertini, MD PhD and just published in @OncologyAdvance #CancerTreatRev We summarized last evidence on #gonadotoxicity, with special focus on new agents in BC treatment Andrea Botticelli OncoAlert #bcsm

#ARTICUNO study finally published! ESMO Open 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit

Big congratulations to Dr. Luis Paz-Ares - the 2024 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer! A brilliant investigator, compassionate clinician, gifted speaker, and a friend to us all. #WCLC24

Finally out!! Clinical utility of combined tissue and plasma NGS in pts w/ advanced, treatment-naïve NSCLC | JTO & JTO CRR 🗞️ @jon_zuga, Luis Paz-Ares, Susana Hernandez Prieto, Esther Conde MD, PhD, Alicia Castelo, marco siringo sciencedirect.com/science/articl…

Finally out the paper: sciencedirect.com/science/articl… I had the huge honour to be mentored by Luis Paz-Ares @jon_zuga and to collaborate with great doctors Helena Bote de Cabo javibaena Mercedes Herrera and many others in my fellowship in Lung Cancer Unit at H12O! Os echo de menos!

Il solito Uragano che si è abbattuto su New York. Serena

Moment of victory for @SerenaWilliams--> wtatenn.is/dQ9VZZ #USOpen #tennis

Con My chance ho provato a vincere i biglietti per #JuveMonaco mychance.juventus.com

One of the things about tennis is getting to meet interesting people from all over the world… ;)